Sun Pharma Advanced Research Company Limited

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUNPHARMA.BO has a market cap of 4.1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUNPHARMA.BO trades at ₹1,713.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUNPHARMA.BO's P/E ratio is 37.90. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SUNPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUNPHARMA.NS has a market cap of 4.1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUNPHARMA.NS trades at ₹1,713.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUNPHARMA.NS's P/E ratio is 37.90. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SUNPHARMA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while DIVISLAB.BO trades at ₹6,293.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas DIVISLAB.BO's P/E ratio is 67.55. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SPARC.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check DIVISLAB.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while DIVISLAB.NS trades at ₹6,297.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas DIVISLAB.NS's P/E ratio is 67.50. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SPARC.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check DIVISLAB.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while TORNTPHARM.NS trades at ₹4,226.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas TORNTPHARM.NS's P/E ratio is 63.05. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, SPARC.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check TORNTPHARM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while TORNTPHARM.BO trades at ₹4,222.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas TORNTPHARM.BO's P/E ratio is 67.00. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, SPARC.NS is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check TORNTPHARM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while DRREDDY.NS trades at ₹1,282.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas DRREDDY.NS's P/E ratio is 18.87. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, SPARC.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check DRREDDY.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while DRREDDY.BO trades at ₹1,279.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas DRREDDY.BO's P/E ratio is 18.87. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, SPARC.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check DRREDDY.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while LUPIN.BO trades at ₹2,228.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas LUPIN.BO's P/E ratio is 23.52. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, SPARC.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check LUPIN.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while LUPIN.NS trades at ₹2,228.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas LUPIN.NS's P/E ratio is 21.89. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, SPARC.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check LUPIN.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ZYDUSLIFE.BO has a market cap of 906.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ZYDUSLIFE.BO trades at ₹902.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ZYDUSLIFE.BO's P/E ratio is 18.37. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to ZYDUSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ZYDUSLIFE.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ZYDUSLIFE.NS has a market cap of 906.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ZYDUSLIFE.NS trades at ₹902.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ZYDUSLIFE.NS's P/E ratio is 18.36. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SPARC.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ZYDUSLIFE.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, MANKIND.BO has a market cap of 836.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while MANKIND.BO trades at ₹2,037.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas MANKIND.BO's P/E ratio is 46.99. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SPARC.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check MANKIND.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, MANKIND.NS has a market cap of 835.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while MANKIND.NS trades at ₹2,039.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas MANKIND.NS's P/E ratio is 46.96. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SPARC.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check MANKIND.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AUROPHARMA.BO has a market cap of 673.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AUROPHARMA.BO trades at ₹1,175.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AUROPHARMA.BO's P/E ratio is 19.69. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, SPARC.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check AUROPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AUROPHARMA.NS has a market cap of 673B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AUROPHARMA.NS trades at ₹1,171.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AUROPHARMA.NS's P/E ratio is 19.29. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, SPARC.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check AUROPHARMA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ALKEM.BO has a market cap of 644.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ALKEM.BO trades at ₹5,374.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ALKEM.BO's P/E ratio is 27.19. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to ALKEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ALKEM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ALKEM.NS has a market cap of 644.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ALKEM.NS trades at ₹5,377.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ALKEM.NS's P/E ratio is 27.62. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to ALKEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ALKEM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GLENMARK.BO has a market cap of 576.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GLENMARK.BO trades at ₹2,020.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GLENMARK.BO's P/E ratio is 54.15. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, SPARC.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check GLENMARK.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GLENMARK.NS has a market cap of 576.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GLENMARK.NS trades at ₹2,016.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GLENMARK.NS's P/E ratio is 54.11. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GLENMARK.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, LAURUSLABS.BO has a market cap of 550.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while LAURUSLABS.BO trades at ₹1,021.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas LAURUSLABS.BO's P/E ratio is 65.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check LAURUSLABS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, LAURUSLABS.NS has a market cap of 550.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while LAURUSLABS.NS trades at ₹1,021.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas LAURUSLABS.NS's P/E ratio is 65.49. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check LAURUSLABS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, SPARC.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SUVENPHAR.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SUVENPHAR.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, IPCALAB.BO has a market cap of 367.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while IPCALAB.BO trades at ₹1,464.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas IPCALAB.BO's P/E ratio is 40.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check IPCALAB.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, IPCALAB.NS has a market cap of 367.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while IPCALAB.NS trades at ₹1,463.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas IPCALAB.NS's P/E ratio is 40.50. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check IPCALAB.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AJANTPHARM.BO has a market cap of 366.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AJANTPHARM.BO trades at ₹2,959.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AJANTPHARM.BO's P/E ratio is 36.21. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SPARC.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AJANTPHARM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AJANTPHARM.NS has a market cap of 366.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AJANTPHARM.NS trades at ₹2,959.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AJANTPHARM.NS's P/E ratio is 36.17. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SPARC.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AJANTPHARM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, JBCHEPHARM.BO has a market cap of 321.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while JBCHEPHARM.BO trades at ₹1,989.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas JBCHEPHARM.BO's P/E ratio is 42.22. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, SPARC.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check JBCHEPHARM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, JBCHEPHARM.NS has a market cap of 321.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while JBCHEPHARM.NS trades at ₹1,992.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas JBCHEPHARM.NS's P/E ratio is 42.18. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, SPARC.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check JBCHEPHARM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, EMCURE.NS has a market cap of 272.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while EMCURE.NS trades at ₹1,435.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas EMCURE.NS's P/E ratio is 31.30. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check EMCURE.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SPARC.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check PEL.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, WOCKPHARMA.NS has a market cap of 224.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while WOCKPHARMA.NS trades at ₹1,392.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas WOCKPHARMA.NS's P/E ratio is 1096.51. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SPARC.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check WOCKPHARMA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, WOCKPHARMA.BO has a market cap of 224.2B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while WOCKPHARMA.BO trades at ₹1,390.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas WOCKPHARMA.BO's P/E ratio is 1095.24. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SPARC.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check WOCKPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ASTRAZEN.BO has a market cap of 222.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ASTRAZEN.BO trades at ₹8,896.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ASTRAZEN.BO's P/E ratio is 110.88. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, SPARC.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ASTRAZEN.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ASTRAZEN.NS has a market cap of 222.2B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ASTRAZEN.NS trades at ₹8,903.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ASTRAZEN.NS's P/E ratio is 110.61. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, SPARC.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ASTRAZEN.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, PPLPHARMA.BO has a market cap of 212.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while PPLPHARMA.BO trades at ₹162.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas PPLPHARMA.BO's P/E ratio is -131.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, SPARC.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check PPLPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ERIS.NS has a market cap of 182.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ERIS.NS trades at ₹1,328.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ERIS.NS's P/E ratio is 42.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, SPARC.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ERIS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ERIS.BO has a market cap of 182.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ERIS.BO trades at ₹1,329.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ERIS.BO's P/E ratio is 42.47. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, SPARC.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ERIS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, NEULANDLAB.BO has a market cap of 162.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while NEULANDLAB.BO trades at ₹13,029.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas NEULANDLAB.BO's P/E ratio is 90.68. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check NEULANDLAB.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, NEULANDLAB.NS has a market cap of 162.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while NEULANDLAB.NS trades at ₹13,020.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas NEULANDLAB.NS's P/E ratio is 90.65. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check NEULANDLAB.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, NATCOPHARM.NS has a market cap of 159.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while NATCOPHARM.NS trades at ₹888.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas NATCOPHARM.NS's P/E ratio is 10.26. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check NATCOPHARM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, NATCOPHARM.BO has a market cap of 159.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while NATCOPHARM.BO trades at ₹888.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas NATCOPHARM.BO's P/E ratio is 10.37. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check NATCOPHARM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, APLLTD.NS has a market cap of 150B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while APLLTD.NS trades at ₹767.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas APLLTD.NS's P/E ratio is 23.78. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, SPARC.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check APLLTD.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, APLLTD.BO has a market cap of 150B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while APLLTD.BO trades at ₹767.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas APLLTD.BO's P/E ratio is 23.79. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, SPARC.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check APLLTD.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GRANULES.NS has a market cap of 145.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GRANULES.NS trades at ₹578.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GRANULES.NS's P/E ratio is 26.65. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check GRANULES.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GRANULES.BO has a market cap of 144.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GRANULES.BO trades at ₹577.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GRANULES.BO's P/E ratio is 26.56. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check GRANULES.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, JUBLPHARMA.NS has a market cap of 138.2B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while JUBLPHARMA.NS trades at ₹867.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas JUBLPHARMA.NS's P/E ratio is 32.06. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, SPARC.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check JUBLPHARMA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, JUBLPHARMA.BO has a market cap of 137.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while JUBLPHARMA.BO trades at ₹866.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas JUBLPHARMA.BO's P/E ratio is 31.89. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, SPARC.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check JUBLPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GLS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GLS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, CAPLIPOINT.NS has a market cap of 128.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while CAPLIPOINT.NS trades at ₹1,704.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas CAPLIPOINT.NS's P/E ratio is 21.04. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SPARC.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check CAPLIPOINT.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, CAPLIPOINT.BO has a market cap of 128.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while CAPLIPOINT.BO trades at ₹1,702.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas CAPLIPOINT.BO's P/E ratio is 21.02. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to CAPLIPOINT.BO's ROE of +0.10%. Regarding short-term risk, SPARC.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check CAPLIPOINT.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, COHANCE.BO has a market cap of 116.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while COHANCE.BO trades at ₹314.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas COHANCE.BO's P/E ratio is 60.37. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check COHANCE.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, COHANCE.NS has a market cap of 116.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while COHANCE.NS trades at ₹315.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas COHANCE.NS's P/E ratio is 60.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check COHANCE.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ALIVUS.BO has a market cap of 111.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ALIVUS.BO trades at ₹889.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ALIVUS.BO's P/E ratio is 20.61. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ALIVUS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ALIVUS.NS has a market cap of 111.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ALIVUS.NS trades at ₹889.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ALIVUS.NS's P/E ratio is 20.58. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ALIVUS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SPARC.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check CAPPL.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, VIYASH.NS has a market cap of 94.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while VIYASH.NS trades at ₹215.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas VIYASH.NS's P/E ratio is 84.02. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, SPARC.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check VIYASH.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, PGHL.NS has a market cap of 83.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while PGHL.NS trades at ₹5,017.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas PGHL.NS's P/E ratio is 35.22. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, SPARC.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check PGHL.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, PGHL.BO has a market cap of 83.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while PGHL.BO trades at ₹5,017.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas PGHL.BO's P/E ratio is 35.22. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, SPARC.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check PGHL.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, STAR.NS has a market cap of 80.2B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while STAR.NS trades at ₹870.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas STAR.NS's P/E ratio is 15.66. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check STAR.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, STAR.BO has a market cap of 80B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while STAR.BO trades at ₹869.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas STAR.BO's P/E ratio is 15.65. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SPARC.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check STAR.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AKUMS.NS has a market cap of 73.2B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AKUMS.NS trades at ₹486.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AKUMS.NS's P/E ratio is 22.87. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, SPARC.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check AKUMS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SHILPAMED.NS has a market cap of 63.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SHILPAMED.NS trades at ₹328.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SHILPAMED.NS's P/E ratio is 28.72. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, SPARC.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SHILPAMED.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AARTIPHARM.BO has a market cap of 63.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AARTIPHARM.BO trades at ₹712.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AARTIPHARM.BO's P/E ratio is 29.65. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, SPARC.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AARTIPHARM.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AARTIPHARM.NS has a market cap of 63.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AARTIPHARM.NS trades at ₹713.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AARTIPHARM.NS's P/E ratio is 29.70. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, SPARC.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AARTIPHARM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, FDC.NS has a market cap of 60.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while FDC.NS trades at ₹376.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas FDC.NS's P/E ratio is 27.76. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, SPARC.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check FDC.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, FDC.BO has a market cap of 60B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while FDC.BO trades at ₹375.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas FDC.BO's P/E ratio is 27.67. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, SPARC.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check FDC.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SPARC.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SEQUENT.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SEQUENT.BO trades at ₹215.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, SPARC.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SEQUENT.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SPARC.BO has a market cap of 41.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SPARC.BO trades at ₹131.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SPARC.BO's P/E ratio is -15.64. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, SPARC.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SPARC.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, INNOVACAP.NS has a market cap of 38.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while INNOVACAP.NS trades at ₹675.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas INNOVACAP.NS's P/E ratio is 28.97. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SPARC.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check INNOVACAP.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GUJTHEM.NS has a market cap of 36.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GUJTHEM.NS trades at ₹327.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GUJTHEM.NS's P/E ratio is 76.48. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, SPARC.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GUJTHEM.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUVEN.NS has a market cap of 34.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUVEN.NS trades at ₹151.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUVEN.NS's P/E ratio is -12.25. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, SPARC.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SUVEN.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SUVEN.BO has a market cap of 34.3B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SUVEN.BO trades at ₹151.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SUVEN.BO's P/E ratio is -12.25. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, SPARC.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check SUVEN.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AARTIDRUGS.BO has a market cap of 34B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AARTIDRUGS.BO trades at ₹370.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AARTIDRUGS.BO's P/E ratio is 16.85. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AARTIDRUGS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, AARTIDRUGS.NS has a market cap of 34B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while AARTIDRUGS.NS trades at ₹370.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas AARTIDRUGS.NS's P/E ratio is 16.85. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, SPARC.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check AARTIDRUGS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ORCHPHARMA.BO has a market cap of 33.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ORCHPHARMA.BO trades at ₹669.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ORCHPHARMA.BO's P/E ratio is 178.72. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, SPARC.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check ORCHPHARMA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ORCHPHARMA.NS has a market cap of 33.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ORCHPHARMA.NS trades at ₹669.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ORCHPHARMA.NS's P/E ratio is 176.29. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SPARC.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ORCHPHARMA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SHILPAMED.BO has a market cap of 31.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SHILPAMED.BO trades at ₹328.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SHILPAMED.BO's P/E ratio is 28.71. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, SPARC.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SHILPAMED.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, RPGLIFE.NS has a market cap of 31.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while RPGLIFE.NS trades at ₹1,926.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas RPGLIFE.NS's P/E ratio is 15.55. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, SPARC.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check RPGLIFE.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, RPGLIFE.BO has a market cap of 31.4B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while RPGLIFE.BO trades at ₹1,922.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas RPGLIFE.BO's P/E ratio is 15.52. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, SPARC.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check RPGLIFE.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GUFICBIO.NS has a market cap of 28.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GUFICBIO.NS trades at ₹286.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GUFICBIO.NS's P/E ratio is 50.80. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, SPARC.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GUFICBIO.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, GUFICBIO.BO has a market cap of 28.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while GUFICBIO.BO trades at ₹286.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas GUFICBIO.BO's P/E ratio is 50.76. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, SPARC.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check GUFICBIO.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, UNICHEMLAB.BO has a market cap of 26B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while UNICHEMLAB.BO trades at ₹367.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas UNICHEMLAB.BO's P/E ratio is 8.83. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SPARC.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check UNICHEMLAB.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, UNICHEMLAB.NS has a market cap of 25.8B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while UNICHEMLAB.NS trades at ₹365.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas UNICHEMLAB.NS's P/E ratio is 8.79. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SPARC.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check UNICHEMLAB.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, HIKAL.BO has a market cap of 25B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while HIKAL.BO trades at ₹202.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas HIKAL.BO's P/E ratio is 253.13. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, SPARC.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check HIKAL.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, HIKAL.NS has a market cap of 24.9B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while HIKAL.NS trades at ₹202.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas HIKAL.NS's P/E ratio is -190.82. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, SPARC.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check HIKAL.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, NOVARTIND.BO has a market cap of 24.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while NOVARTIND.BO trades at ₹830.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas NOVARTIND.BO's P/E ratio is 25.28. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, SPARC.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check NOVARTIND.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, ALEMBICLTD.NS has a market cap of 24.1B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while ALEMBICLTD.NS trades at ₹93.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas ALEMBICLTD.NS's P/E ratio is 7.45. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, SPARC.NS is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check ALEMBICLTD.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, BLISSGVS.NS has a market cap of 23.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while BLISSGVS.NS trades at ₹226.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas BLISSGVS.NS's P/E ratio is 21.91. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, SPARC.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check BLISSGVS.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, BLISSGVS.BO has a market cap of 23.6B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while BLISSGVS.BO trades at ₹226.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas BLISSGVS.BO's P/E ratio is 21.93. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, SPARC.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check BLISSGVS.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SOLARA.BO has a market cap of 22.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SOLARA.BO trades at ₹478.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SOLARA.BO's P/E ratio is -97.74. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, SPARC.NS is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SOLARA.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, SOLARA.NS has a market cap of 22.7B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while SOLARA.NS trades at ₹478.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas SOLARA.NS's P/E ratio is -97.62. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, SPARC.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SPARC.NS.Check SOLARA.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, MOREPENLAB.BO has a market cap of 21.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while MOREPENLAB.BO trades at ₹37.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas MOREPENLAB.BO's P/E ratio is 21.96. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check MOREPENLAB.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, IOLCP.BO has a market cap of 21.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while IOLCP.BO trades at ₹74.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas IOLCP.BO's P/E ratio is 18.57. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, SPARC.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check IOLCP.BO's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, IOLCP.NS has a market cap of 21.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while IOLCP.NS trades at ₹74.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas IOLCP.NS's P/E ratio is 18.56. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, SPARC.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check IOLCP.NS's competition here

SPARC.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SPARC.NS stands at 41.9B. In comparison, MOREPENLAB.NS has a market cap of 21.5B. Regarding current trading prices, SPARC.NS is priced at ₹130.88, while MOREPENLAB.NS trades at ₹37.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SPARC.NS currently has a P/E ratio of -15.66, whereas MOREPENLAB.NS's P/E ratio is 22.29. In terms of profitability, SPARC.NS's ROE is +1.25%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, SPARC.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SPARC.NS.Check MOREPENLAB.NS's competition here